All In Biotech

Drug Trial Radar · NCT00597584

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin

Last checked: Nov 19, 2026Latest source record: Mar 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 823 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

823

Actual

Start

Oct 2007

Primary completion

Jul 2009

Study completion Jan 2010

Sponsor

Lead sponsor
AffymaxIndustry
Sponsor type
Industry
Collaborators
Takeda
First posted
Jan 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.

Conditions

  • Chronic Renal Failure
  • Chronic Kidney Disease
  • Anemia

Interventions

  • peginesatideDrug

    Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.

  • Epoetin alfa or Epoetin betaDrug

    Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Hemoglobin Between Baseline and the Evaluation PeriodTime frame: Baseline to Weeks 29-36

Locations

84 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Facility

    Phoenix, Arizona

  • Research Facility

    Hot Springs, Arkansas

  • Research Facility

    McGehee, Arkansas

  • Research Facility

    Pine Bluff, Arkansas

  • Research Facility

    Bakersfield, California

  • Research Facility

    Glendale, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Riverside, California

  • Research Facility

    Simi Valley, California

  • Research Facility

    Whittier, California

  • Research Facility

    Yuba City, California

  • Research Facility

    Westminster, Colorado

  • Research Facility

    Lauderdale Lakes, Florida

  • Research Facility

    Miami, Florida

  • Research Facility

    Pinecrest, Florida

  • Research Facility

    Flossmoor, Illinois

  • Research Facility

    Hines, Illinois

  • Research Facility

    Louisville, Kentucky

  • Research Facility

    Rockville, Maryland

  • Research Facility

    Springfield, Massachusetts

  • Research Facility

    Detroit, Michigan

  • Research Facility

    Detroit, Michigan

  • Research Facility

    Brookhaven, Mississippi

  • Research Facility

    Brooklyn, New York

  • Research Facility

    Flushing, New York

  • Research Facility

    The Bronx, New York

  • Research Facility

    Asheville, North Carolina

  • Research Facility

    Toledo, Ohio

  • Research Facility

    Oklahoma City, Oklahoma

  • Research Facility

    Erie, Pennsylvania

  • Research Facility

    Philadelphia, Pennsylvania

  • Research Facility

    Providence, Rhode Island

  • Research Facility

    Orangeburg, South Carolina

  • Research Facility

    Arlington, Texas

  • Research Facility

    Houston, Texas

  • Research Facility

    San Antonio, Texas

  • Research Facility

    Fairfax, Virginia

  • Research Facility

    Burgas, Bulgaria

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.